Genhouse Bio
China - SuzhouBiotechnology
Focus: Genhouse Bio is a China-based biotechnology company focused on developing small molecule cancer therapies targeting advanced solid tumors with specific genetic mutations. The company operates as a clinical-stage oncology specialist with a pipeline of 11 programs across Phase 1-2 development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Genhouse Bio
AI assessmentNot HiringNo open roles listed right now. Follow Genhouse Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
11 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GH2616 Tablets
Advanced Solid TumorsClinical Trials (1)
NCT06329206A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Phase 1Help build intelligence for Genhouse Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.